Compare UEC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEC | PCVX |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | UEC | PCVX |
|---|---|---|
| Price | $17.14 | $48.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $15.80 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 10.6M | 1.2M |
| Earning Date | 12-10-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,750,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $153.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 189.19 | N/A |
| 52 Week Low | $3.85 | $27.66 |
| 52 Week High | $17.80 | $93.77 |
| Indicator | UEC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 59.92 |
| Support Level | $11.65 | $44.57 |
| Resistance Level | $14.59 | $47.72 |
| Average True Range (ATR) | 0.92 | 2.00 |
| MACD | 0.43 | 0.11 |
| Stochastic Oscillator | 90.96 | 79.84 |
Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.